MEAM identifies high-risk MPN patients that conventional scoring systems miss—particularly younger patients under 60 who are often classified as low risk despite adverse outcomes.
Ground Truth Labs
Team
Our largest clinical evaluation of CIF to date: across 1000 cases and 15 international pathologists, AI augmentation more than doubled the odds of consensus in fibrosis grading.
Ground Truth Labs
Team
At ASH 2024, we presented findings showing that manual blast cell assessment consistently overestimates counts compared to AI—with implications for patient classification.
Xuezi Hu
Machine Learning Scientist
Our CIF technology has been demonstrated in a multicenter Phase II clinical trial—the first application of AI-driven quantitative fibrosis analysis in this setting.
Ground Truth Labs
Team
We're delighted to announce two of our abstracts have been accepted for presentation at the European Hematology Association 2024 Conference.
Ground Truth Labs
Team
GTL's AI biomarker platform recognized for its potential to revolutionize cancer diagnosis and treatment.
Ground Truth Labs
Team
Ground Truth Labs highlights ASH 2023's innovative MPN therapies and advances AI-driven fibrosis assessment to revolutionize treatment approaches.
Róisín NicAmhlaoibh
VP Business Development
Daniel Royston, pathology lead at Ground Truth Labs, discusses the role of AI in bone marrow histology with MPN Hub.
Daniel Royston
Pathology Lead
The vital role of novel research and development in tackling blood cancers like myeloproliferative neoplasms and myeloma.
Ground Truth Labs
Team
AI biomarkers will transform oncology with new maps for tumor biology and breakthrough predictors for treatment response. We have the opportunity to improve outcomes for every cancer patient with AI-driven insights from digital pathology.
Alan Aberdeen
Co-founder
Today, Ground Truth Labs (GTL), is thrilled to announce its launch into the wider healthtech space. Backed by a $4.3M funding round led by Oxford Science Enterprises
Ground Truth Labs
Team